$0.05
+11.67%Price chart
Jul 27Aug 5Aug 11Aug 14Aug 21Aug 27Sep 9Sep 17
Key dataSep 17, 2026
Open$0.05
From 52W high−87.49%
Volume4.00
Market cap$1.32M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 17, 2026
Open
$0.05
From 52W high
−87.49%
Volume
4.00
Market cap
$1.32M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
P/E (TTM)
—
RSI (14)
48.6
MomentumView details →
1D Return
+11.67%
YTD Return
+39.43%
SummaryUpdated Jun 1, 2026
Liminatus Pharma, Inc. (NASDAQ:LIMNW) is a clinical-stage immuno-oncology biotechnology company founded and based in La Palma, California. The company went public in April 2025 and focuses on developing novel cancer therapies that harness the body's immune system to fight cancer. As a pre-revenue biotechnology company, Liminatus is in the early stages of drug development, working to advance its therapeutic candidates through clinical trials with the ultimate goal of bringing new cancer treatments to market.
Similar companies
Latest newsMore news →
Liminatus Pharma, Inc. announced a 1-for-50 reverse stock split of its common stock, approved by its board and stockholders at the 2026 Annual Meeting held on August 3, 2026.33d agoLiminatus Pharma, Inc. received a notice from NASDAQ on 2026-08-12 that it is not in compliance with Listing Rule 5550(a)(2) regarding minimum bid price, and plans to implement a 1-for-50 reverse stock split.34d agoLiminatus Pharma, Inc. issued 11,188,729 shares of common stock and 158,881.1271 shares of newly designated Series A Non-Voting Convertible Preferred Stock in connection with its merger, exempt from registration under Section 4(a)(2) of the Securities Act of 1933.77d ago